{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:43Z","timestamp":1793643343293,"version":"4.5.1"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,11,15]]},"DOI":"10.2169\/internalmedicine.1163-22","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T22:25:42Z","timestamp":1680215142000},"page":"3381-3385","source":"Crossref","is-referenced-by-count":4,"title":["Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma"],"prefix":"10.2169","volume":"62","author":[{"given":"Toshiyuki","family":"Sumi","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan"},{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Michimata","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan"},{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Nagayama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan"},{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Koshino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan"},{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Nishikiori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. National Comprehensive Cancer Network 2022. Immunotherapy side effects: immune checkpoint inhibitors [Internet]. Available from: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/immunotherapy-se-ici-patient.pdf"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Thomas CF Jr, Limper AH. <i>Pneumocystis<\/i> pneumonia. N Engl J Med 350: 2487-2498, 2004.","DOI":"10.1056\/NEJMra032588"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Maini R, Henderson KL, Sheridan EA, et al. Increasing <i>Pneumocystis<\/i> pneumonia, England, UK, 2000-2010. Emerg Infect Dis 19: 386-392, 2013.","DOI":"10.3201\/eid1903.121151"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189-194, 2008.","DOI":"10.1136\/ard.2007.072967"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Morris A, Norris KA. Colonization by <i>Pneumocystis jirovecii<\/i> and its role in disease. Clin Microbiol Rev 25: 297-317, 2012.","DOI":"10.1128\/CMR.00013-12"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Del Castillo M, Romero FA, Arg\u00fcello E, Kyi C, Postow MA, Redelman-Sidi G. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 63: 1490-1493, 2016.","DOI":"10.1093\/cid\/ciw539"},{"key":"7","doi-asserted-by":"crossref","first-page":"e1040218","DOI":"10.1080\/2162402X.2015.1040218","volume":"4","author":"E Arriola","year":"2015","unstructured":"7. Arriola E, Wheater M, Krishnan R, Smart J, Foria V, Ottensmeier C. Immunosuppression for ipilimumab-related toxicity can cause <i>pneumocystis<\/i> pneumonia but spare antitumor immune control. Oncoimmunology 4: e1040218, 2015.","journal-title":"OncoImmunology","ISSN":"https:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Si S, Erickson K, Evageliou N, Silverman M, Kersun L. An usual presentation of <i>Pneumocystis jirovecii<\/i> pneumonia in a woman treated with immune checkpoint inhibitor. J Pediatr Hematol Oncol 43: e163-e164, 2021.","DOI":"10.1097\/MPH.0000000000001757"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sepkowitz KA, Brown AE, Armstrong D. <i>Pneumocystis carinii<\/i> pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 155: 1125-1128, 1995.","DOI":"10.1001\/archinte.155.11.1125"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35: 709-717, 2017.","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Asai N, Motojima S, Ohkuni Y, et al. Pathophysiological mechanism of non-HIV <i>Pneumocystis jirovecii<\/i> pneumonia. Respir Investig 60: 522-530, 2022.","DOI":"10.1016\/j.resinv.2022.04.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35: 169-178, 2012.","DOI":"10.1097\/CJI.0b013e318247a4e7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Zhang C, Rong HM, Li T, Zhai K, Tong ZH. PD-1 deficiency promotes macrophage activation and T-helper cell type 1\/T-helper cell type 17 response in <i>Pneumocystis<\/i> pneumonia. Am J Respir Cell Mol Biol 62: 767-782, 2020.","DOI":"10.1165\/rcmb.2019-0234OC"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cho SJ, Stout-Delgado HW. Aging and lung disease. Annu Rev Physiol 82: 433-459, 2020.","DOI":"10.1146\/annurev-physiol-021119-034610"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Vera C, Rueda ZV. Transmission and colonization of <i>Pneumocystis jirovecii<\/i>. J Fungi (Basel) 7: 979, 2021.","DOI":"10.3390\/jof7110979"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hiba Z, Abdelmoughit H, Zaynab IH, Hounaida J, Rachida L, Youssef O. Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab. Radiol Case Rep 17: 3979-3981, 2022.","DOI":"10.1016\/j.radcr.2022.07.083"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sadek M, Loizidou A, Drowart A, Van den Wijngaert S, Gomez-Galdon M, Aspeslagh S. Pneumocystis infection in two patients treated with both immune checkpoint inhibitor and corticoids. J Immunother Precis Oncol 3: 27-30, 2020.","DOI":"10.4103\/JIPO.JIPO_23_19"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Takata S, Koh G, Han Y, et al. Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-<i>Mycobacterium tuberculosis<\/i> agents. J Infect Chemother 25: 54-58, 2019.","DOI":"10.1016\/j.jiac.2018.06.016"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Anastasopoulou A, Ziogas DC, Samarkos M, Kirkwood JM, Gogas H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer 7: 239, 2019.","DOI":"10.1186\/s40425-019-0717-7"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/22\/62_1163-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:29:47Z","timestamp":1715574587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/22\/62_1163-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":19,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1163-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"article-number":"1163-22"}}